Evolus (EOLS) Stock Forecast & Price Target

Evolus is supported by resilient demand in the cash-pay aesthetic market, where management saw continued prioritization of treatments despite inflationary headwinds and raised 2026 revenue guidance to $327M-$337M, while Jeuveau’s 14% U.S. share provides a durable base. Growth is increasingly driven by Evolysse, with about 3,500 accounts, rising reorder rates, and accounts buying both Jeuveau and Evolysse generating 2.5x greater volume year-to-date, highlighting strong portfolio synergy and room for expansion as Sculpt nears FDA approval in 4Q26. The company has also delivered two consecutive quarters of positive adjusted EBITDA, and with approximately $50M of cash plus available debt capacity and a terminated ATM facility, it appears well positioned to fund product additions and move toward sustainable profitability.

Evolus is exposed to a challenging competitive and execution backdrop, with risks from larger competitors, pricing pressure, and the possibility that Jeuveau and Evolysse fail to gain share as expected. The cited framework values the business off a 2035 discounted risk-adjusted revenue estimate of $215M, but that outlook is tempered by a 60% probability of success for Evolysse and the need to defend a commercial portfolio against supply chain disruption and potential tariffs. A deteriorating consumer spending environment, higher-than-expected operating expenses, regulatory delays, and possible dilution further weaken the fundamental case and support a negative outlook.